Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Eli Lilly continues its remarkable market ascension as the pharmaceutical giant capitalizes on rival Novo Nordisk's struggles ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast cancer awareness activations.

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also ...

INDIANAPOLIS, Ind. — Eli Lilly and Co. announced plans for a major nationwide investment to expand operations, including an $85 million commitment in Indianapolis. It’s part of an overall $85… ...

Eli Lilly and Company will expand its global R&D headquarters in Indianapolis, IN, adding 130,000 square feet to the company's existing complex.

Eli Lilly and Co., announced Wednesday that it will reduce the price of insulin and cap the monthly cost to most of its insulin users at $35 starting in May, putting the life saving drug within ...